Abnormal growth of the tissues in the inside layer of the bladder is usually referred to as bladder cancer. These abnormal tissues are known as tumor, they can spread to the nearby tissues or muscles. Bladder cancer is the ninth most common forms of cancer worldwide in men and women, with the highest recurrence rate. Muscle-invasive and non-muscle-invasive are two types of bladder cancer. Non-muscle-invasive bladder cancer is the most common type of bladder cancer, which is less fatal. It is also termed as superficial bladder cancer; wherein, the tumor grows inside the lining of the bladder. Muscle-invasive bladder cancer occurs when the tumor spreads outside the lining of the bladder. This form of bladder cancer is very rare and fatal. Transurethral resection of the tumor is the standard treatment for non-muscle-invasive bladder cancer, which is then followed by perioperative chemotherapy. Patients undergo yearly checkups owing to the cancer’s recurrent tendency. Last decade has witnessed a substantial improvement in the bladder cancer treatment; however, high unmet needs still remain unfilled. Prevalence of bladder cancer and growing awareness regarding its types and their treatment are major factors contributing to the significant growth of the global bladder cancer treatment drugs market.
Based on type, the global bladder cancer treatment drugs market can be segmented into
- Non-muscle-invasive bladder cancer
- Muscle-invasive bladder cancer
In terms of malignant potential, the market can be bifurcated into
- Low-grade tumors
- High-grade tumors
The increase in prevalence of bladder cancer, advanced health care services, technological advancements, drug innovations with regard to the treatment of this cancer for ex launch of EOquin, and government initiatives could contribute to the growth of the bladder cancer treatment drugs market. Majority of bladder cancer patients are over the age of 60. Rise in the geriatric population is anticipated to drive the market growth. Additionally, growing awareness about bladder diseases, therapies available in the market, and increasing health care expenditure are significantly contributing toward the growth of the global bladder cancer treatment drugs market. However, rise in number of patent expirations, increase in use of generic drugs, and asymptomatic nature of the disease are some major factors that could hamper the growth of the market.
North America dominates the bladder cancer treatment drugs market followed by Europe. Rise in bladder cancer cases, availability of advanced health care solutions, developed health care infrastructure, and growing concern regarding the disease in these regions are key factors attributed to the significant market share. However, rapidly increasing prevalence of bladder cancer in the Asia Pacific region, in which India being the major country having large number of patients suffering from this disease, is expected to experience a high growth rate in the bladder cancer treatment drugs market over the forecast period. Further, increasing awareness about cancer diagnosis, growing demand for improved bladder cancer treatments and therapies, developing health care infrastructure, and rising health care expenditure in the region can drive the market growth.
Major players operating in the global bladder cancer treatment drugs market include Pfizer, Inc., GlaxoSmithKline, Celgene Corporation, Sanofi S.A, F. Hoffmann-La Roche, Novartis International AG, Eli Lilly and Co., AstraZeneca plc., and Bristol-Myers Squibb.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.